Important note: Information in this article was accurate in 2004. The state of the art may have changed since the publication date.  |
AIDS TREATMENT NEWS - October 26, 2004
John S. James
Summary: A study of medical records found that combining the antibiotic erythromycin with strong inhibitors of the liver enzyme CYP3A increased the risk of sudden death from cardiac causes -- probably by abnormally raising the blood levels of erythromycin.
----------------------------------------
An article in the September 9, 2004 New England Journal of Medicine reported that patients using the antibiotic erythromycin at the same time as drugs that strongly inhibited cytochrome P-450 3A (CYP3A, an enzyme in the liver that helps remove many drugs from the body) had an increased risk of sudden death from cardiac (heart) causes. But those who used amoxicillin, a different antibiotic, instead of erythromycin, did not have the problem. The authors concluded "concurrent use of erythromycin and strong inhibitors of CYP3A should be avoided."
The patients in this study were using oral erythromycin (not the injected form, which is probably more dangerous because of the higher blood levels reached).
This study of Tennessee Medicaid recipients excluded those with HIV or other life-threatening conditions, so patients taking antiretrovirals were not included. But the mechanism of the drug interaction is well known (inhibition of the enzyme dangerously increases the erythromycin level, which can affect the heart rhythm) and it is clear that HIV protease inhibitors would also be a risk if used at the same time as the erythromycin.
In this study of medical records there were 194 person-years on erythromycin plus strong P-450 3A inhibitors at the same time, and three sudden deaths from cardiac causes. This is statistically significant, despite the small number of deaths, because none or one would have been expected.
Previous use of erythromycin in patients taking the enzyme inhibitors was also checked, and was not a problem. The dangerous blood levels occur when the drugs are used concurrently.
References
1. Ray WA, Murray KT, Meredith S, and others. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004 Sep 9;351(11):1089-96.
041026
ATN041003
Copyright © 2004 - by John S. James. See "Permission to Copy" at: http://www.aidsnews.org/canhelp. How to help AIDS Treatment News: http://www.aidsnews.org/canhelp.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .